publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
alt
alanin
aminotransferas
hbsag
hepat
b
surfac
antigen
pt
prothrombin
time
tb
total
bilirubin
editor
march
hospit
outbreak
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscoronaviru
sarscov
report
hong
kong
case
subsequ
report
global
studi
investig
pattern
hepat
damag
well
effect
chronic
hepat
b
clinic
outcom
sar
retrospect
analysi
patient
cohort
report
previous
lamivudin
mg
daili
prescrib
chronic
hepat
b
patient
oxygen
therapi
given
patient
oxygen
satur
fell
mechan
ventil
offer
patient
could
achiev
oxygen
satur
lmin
oxygen
supplement
anticoronaviru
immunoglobulin
ig
g
antibodi
measur
immunoflouresc
assay
pair
sera
sampl
histolog
electronmicroscop
examin
perform
autopsi
liver
specimen
liver
tissu
sampl
inocul
onto
african
green
monkey
kidney
vero
monolay
viral
isol
revers
transcriptas
polymeras
chain
reaction
rtpcr
perform
confirm
presenc
sarscov
posit
cell
cultur
categor
variabl
compar
use
chisquar
test
continu
variabl
use
mannwhitney
u
test
test
statist
signific
taken
p
one
hundr
eighteen
patient
hepat
b
surfac
antigen
hbsag
result
avail
studi
pair
serum
sampl
sarscov
serolog
avail
patient
posit
baselin
characterist
clinic
outcom
patient
shown
tabl
two
chronic
hepat
b
patient
liver
cirrhosi
among
patient
without
cirrhosi
admit
chronic
hepat
b
flareup
contract
sar
nosocomi
admiss
patient
elev
alanin
aminotransferas
level
patient
normal
level
one
patient
die
respiratori
failur
relat
sar
anoth
die
multiorgan
failur
among
survivor
alanin
aminotransferas
level
patient
return
normal
patient
decreas
followup
among
hbsagneg
patient
patient
elev
alanin
aminotransferas
level
admiss
none
patient
comorbid
ill
taken
medic
seventyon
percent
patient
normal
baselin
level
experienc
elev
alanin
aminotransferas
cours
ill
clinic
outcom
includ
oxygen
requir
need
intub
case
fatal
rate
differ
patient
normal
elev
baselin
alanin
aminotransferas
level
patient
develop
liver
failur
overal
patient
experienc
alanin
aminotransferas
elev
normal
alanin
aminotransferas
level
discharg
anoth
patient
decreas
level
followup
autopsi
perform
patient
includ
chronic
hepat
b
patient
die
specif
hepat
lesion
acut
hepatit
chang
hepat
necrosi
observ
coronaviru
particl
detect
electromicroscopi
posit
cell
cultur
sarscov
confirm
rtpcr
found
patient
normal
alanin
aminotransferas
level
throughout
admiss
studi
threequart
patient
experienc
alanin
aminotransferas
elev
level
major
return
normal
recoveri
liver
derang
sar
like
nonspecif
transient
reaction
caus
infect
rather
direct
cytopath
effect
sarscov
clinic
outcom
chronic
hepat
b
patient
differ
hbsagneg
patient
contrast
outcom
previou
report
absenc
specif
hepat
lesion
hepat
b
viru
sarscov
coinfect
patient
autopsi
support
lack
influenc
sar
chronic
hepat
b
infect
conclus
found
chronic
hepat
b
viru
infect
influenc
clinic
outcom
sar
sar
patient
transient
elev
liver
enzym
level
seriou
clinic
consequ
henri
l
chan
md
waikeung
leung
md
wasp
third
common
venom
anim
respons
human
fatal
unit
state
clinic
manifest
wasp
sting
divid
three
group
local
reaction
pain
wheal
edema
swell
gener
selflimit
immunolog
reaction
usual
lead
anaphylaxi
subsequ
anaphylact
shock
system
toxic
reaction
caus
larg
dose
venom
result
hemolysi
coagulopathi
rhabdomyolysi
acut
renal
failur
hepatotox
describ
case
massiv
vespa
affini
sting
associ
acut
descend
aortic
thrombosi
cerebr
infarct
uncommon
follow
wasp
sting
therefor
extend
clinic
spectrum
wasp
envenom
woman
without
remark
medic
histori
stung
swarm
wasp
initi
itchi
pain
sensat
note
venomexpos
site
twentyfour
hour
envenom
complain
sudden
onset
rightsid
mouth
angl
deviat
numb
weak
left
limb
follow
paraplegia
comput
tomograph
ct
scan
brain
show
normal
result
blood
pressur
mm
hg
physic
examin
reveal
cold
lower
limb
weak
pulsat
bilater
dorsali
pedi
arteri
gener
muscl
tender
shallow
left
nasolabi
fold
left
hemiplegia
paraplegia
absent
bilater
extensor
plantar
reflex
hyporeflexia
lower
limb
estim
sting
head
face
limb
platelet
count
l
prothrombin
time
intern
normal
ratio
activ
partial
thromboplastin
time
second
control
second
note
coagulopathi
elev
ddimer
level
ngdl
refer
ngdl
elev
fibrinogen
degrad
product
gml
refer
gml
posit
protamin
sulfat
time
biochem
test
reveal
follow
valu
blood
